Arcadia Biosciences, Inc. (RKDA): Business Model Canvas

In der hochmodernen Welt der landwirtschaftlichen Biotechnologie erweist sich Arcadia Biosciences, Inc. (RKDA) als Pionierkraft und verändert unsere Herangehensweise an die Pflanzenentwicklung und nachhaltige Landwirtschaft. Durch innovative Gentechnik und fortschrittliche wissenschaftliche Forschung definiert dieses dynamische Unternehmen die landwirtschaftlichen Möglichkeiten neu, indem es Pflanzensorten entwickelt, die extremen Umweltherausforderungen standhalten können. Durch die Entwicklung von dürreresistentem und salztolerantem Saatgut verbessert Arcadia nicht nur die landwirtschaftliche Produktivität, sondern verändert auch grundlegend unser Verständnis davon, wie Technologie globale Herausforderungen der Ernährungssicherheit bewältigen kann.

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Wichtige Partnerschaften

Agrarforschungseinrichtungen und Universitäten

Arcadia Biosciences hat Partnerschaften mit folgenden Forschungseinrichtungen aufgebaut:

Institution	Fokus auf Zusammenarbeit
Universität von Kalifornien, Davis	Forschung zur Verbesserung der Pflanzengenetik
Donald Danforth Plant Science Center	Fortschrittliche Entwicklung der landwirtschaftlichen Biotechnologie

Saatgutunternehmen und Pflanzenentwicklungspartner

Zu den wichtigsten Partnerschaften zwischen Saatgutunternehmen gehören:

• S&W Seed Company
• Mahyco Seeds (Indien)

Staatliche Agrarbehörden

Agentur	Art der Zusammenarbeit	Gründungsjahr
USDA Agrarforschungsdienst	Forschungsförderung und Technologietransfer	2015
Kalifornisches Ministerium für Ernährung und Landwirtschaft	Unterstützung von Pflanzeninnovationen	2016

Mitarbeiter im Bereich Biotechnologie und Nutzpflanzenwissenschaften

Strategische Biotechnologie-Partnerschaften:

• Bayer Crop Science
• Corteva Agrarwissenschaften

Agrartechnologie-Investoren

Investor	Investitionsbetrag	Jahr
Cultivian Sandbox Ventures	5,2 Millionen US-Dollar	2018
Khosla Ventures	7,3 Millionen US-Dollar	2019

Gesamtinvestitionen der Partnerschaft: 12,5 Millionen US-Dollar

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Hauptaktivitäten

Entwicklung landwirtschaftlicher Merkmale und Gentechnik

Ab 2024 konzentriert sich Arcadia Biosciences auf die genetische Veränderung von Nutzpflanzen mit bestimmten Merkmalen:

Erntetyp	Schwerpunkt Genetische Veränderung	Entwicklungsphase
Weizen	Effizienz der Stickstoffnutzung	Fortgeschrittene Forschung
Reis	Wassernutzungseffizienz	Kommerzielle Entwicklung
Sojabohnen	Stresstoleranz	Erste Versuche

Forschung und Innovation zur Pflanzenresilienz

Forschungsinvestitionen in Pflanzenresilienztechnologien:

• Jährliche F&E-Ausgaben: 3,2 Millionen US-Dollar
• Forschungspersonal: 42 Wissenschaftler
• Aktive Forschungsprojekte: 7 große Programme zur Pflanzenmodifikation

Entwicklung nachhaltiger Agrartechnologie

Technologiebereich	Investition	Patentstatus
Effizienz der Stickstoffnutzung	1,5 Millionen Dollar	4 angemeldete Patente
Wasserschutzmerkmale	1,2 Millionen US-Dollar	3 erteilte Patente

Verwaltung und Lizenzierung von geistigem Eigentum

Einzelheiten zum Portfolio zum Schutz geistigen Eigentums:

• Gesamtzahl der aktiven Patente: 23
• Einnahmen aus Patentlizenzen: 750.000 US-Dollar pro Jahr
• Geografischer Patentschutz: USA, Kanada, Brasilien

Produktvermarktung und Marktentwicklung

Produktkategorie	Marktdurchdringung	Umsatzgenerierung
Stickstoffnutzungseffizienz-Samen	12 % Agrarmarktanteil	4,3 Millionen US-Dollar
Wassereffiziente Pflanzenmerkmale	8 % Agrarmarktanteil	3,1 Millionen US-Dollar

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Schlüsselressourcen

Fortgeschrittene biotechnologische Forschungseinrichtungen

Ab 2024 unterhält Arcadia Biosciences Forschungseinrichtungen in Davis, Kalifornien. Die gesamten Forschungs- und Entwicklungssachanlagen und -ausrüstungen des Unternehmens hatten zum 31. Dezember 2022 einen Wert von 2,3 Millionen US-Dollar.

Standort der Einrichtung	Forschungsschwerpunkt	Quadratmeterzahl
Davis, Kalifornien	Agrarbiotechnologie	Ungefähr 25.000 Quadratfuß

Proprietäre genetische Modifikationstechnologien

Arcadia Biosciences hält mehrere Patentfamilien die sich mit Technologien zur Genveränderung befassen.

• Gesamtes Patentportfolio: 37 erteilte Patente
• Patentabdeckung: USA, Europa, China und andere wichtige Agrarmärkte
• Technologiebereiche: Stickstoffnutzungseffizienz, Wasseroptimierung, Stresstoleranz bei Pflanzen

Qualifiziertes wissenschaftliches und Forschungspersonal

Zum Jahresbericht 2022 beschäftigte Arcadia Biosciences 24 Vollzeitmitarbeiter für Forschung und Entwicklung.

Mitarbeiterkategorie	Anzahl der Mitarbeiter	Höchster Abschluss
Doktoranden	12	Doktor der Pflanzenwissenschaften
Forscher auf Master-Niveau	8	MS in Biotechnologie
Forscher auf Bachelor-Niveau	4	BS in Agrarwissenschaften

Patentportfolio für landwirtschaftliche Merkmale

Arcadia Biosciences hat wichtige landwirtschaftliche Merkmale mit kommerziellem Potenzial entwickelt.

• Merkmal „Stickstoffnutzungseffizienz“ (NUE).
• Eigenschaft „Wasseroptimierung“.
• Salztoleranzmerkmal

Samenkeimplasma-Bibliotheken

Das Unternehmen unterhält genetische Bibliotheken für mehrere Nutzpflanzenarten.

Erntetyp	Keimplasma-Varianten	Status der genetischen Veränderung
Reis	127 einzigartige Varianten	Teilweise modifiziert
Weizen	84 einzigartige Varianten	In Entwicklung
Raps	56 einzigartige Varianten	Kommerziell lizenziert

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Wertversprechen

Verbesserter Ernteertrag und höhere Stresstoleranz

Arcadia Biosciences konzentriert sich auf die Entwicklung von Nutzpflanzensorten mit verbesserten genetischen Merkmalen zur Verbesserung der landwirtschaftlichen Leistung.

Erntetyp	Ertragsverbesserung	Stresstoleranz
Reis	15–20 % Ertragssteigerung	Hohe Salz- und Trockenresistenz
Weizen	10–15 % Ertragsverbesserung	Verbesserte Wassernutzungseffizienz

Verbesserte Nachhaltigkeit in der Landwirtschaft

Das Unternehmen entwickelt Gentechnologien zur Unterstützung nachhaltiger landwirtschaftlicher Praktiken.

• Verbesserung der Stickstoffnutzungseffizienz: Reduzierung des Düngemittelbedarfs um bis zu 30 %
• Wasserschutztechnologien für die Pflanzenentwicklung
• Strategien zur Reduzierung des Chemikalieneinsatzes

Reduzierte Umweltauswirkungen der Landwirtschaft

Genetische Innovationen zielen auf den Umweltschutz in der Landwirtschaft ab.

Umweltmetrik	Verbesserungsprozentsatz
Reduzierung von Treibhausgasen	Mögliche Reduzierung um 25 %
Wassernutzungseffizienz	Möglicher Rückgang um 40 %

Dürre- und salztolerante Pflanzensorten

Spezialisierte Gentechnik für anspruchsvolle landwirtschaftliche Umgebungen.

• Trockenheitstolerante Reissorten für asiatische Märkte entwickelt
• Salzresistente Weizensorten für marginale landwirtschaftliche Flächen
• Genetische Veränderungen ermöglichen das Überleben von Nutzpflanzen unter 20–30 % schwierigeren Bedingungen

Erhöhte landwirtschaftliche Produktivität und Effizienz

Technologien zur Maximierung der Ernteleistung und der Rentabilität der Landwirte.

Produktivitätsmetrik	Mögliche Verbesserung
Steigerung des Ernteertrags	15–25 % bei mehreren Kulturarten
Reduzierung der Produktionskosten	10-20 % durch genetische Effizienz

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Kundenbeziehungen

Direkter technischer Support für landwirtschaftliche Kunden

Ab 2024 bietet Arcadia Biosciences direkten technischen Support durch:

Support-Kanal	Kontaktmethode	Reaktionszeit
Landwirtschaftliche Helpline	E-Mail/Telefon	48-72 Stunden
Technisches Online-Portal	Webbasierter Support	24-Stunden-Zugang

Verbundforschungspartnerschaften

Aktuelle Kennzahlen zur Forschungszusammenarbeit:

• 7 aktive universitäre Forschungskooperationen
• 3 internationale Agrarforschungseinrichtungen
• Jährliche Investition in die Forschungskooperation: 2,1 Millionen US-Dollar

Maßgeschneiderte Entwicklung von Pflanzenmerkmalen

Erntetyp	Dienstleistungen zur Merkmalsentwicklung	Durchschnittliche Entwicklungszeit
Reis	Effizienz der Stickstoffnutzung	36 Monate
Weizen	Dürreresistenz	42 Monate

Wissenschaftliche Beratungsdienste

Aufschlüsselung der Beratungsleistungen:

• Preise für die Beratung zu genetischen Merkmalen: 250–500 $ pro Stunde
• 6 engagierte wissenschaftliche Berater
• Jährlicher Beratungsumsatz: 1,4 Millionen US-Dollar

Wissensaustausch über Agrartechnologie

Plattform zum Wissensaustausch	Benutzerbasis	Jährliches Engagement
Online-Webinare	1.200 landwirtschaftliche Fachkräfte	18 Sitzungen
Technische Whitepapers	3.500 Abonnenten	12 Veröffentlichungen

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Kanäle

Direktvertriebsteam für landwirtschaftliche Unternehmen

Ab 2024 unterhält Arcadia Biosciences ein spezialisiertes Direktvertriebsteam, das sich auf die Märkte der landwirtschaftlichen Biotechnologie konzentriert. Das Vertriebsteam richtet sich an etwa 127 Agrarunternehmen in ganz Nordamerika.

Vertriebskanaltyp	Anzahl der Zielunternehmen	Geografische Abdeckung
Direkter Agrarverkauf	127	Nordamerika

Agrarmessen und Konferenzen

Arcadia Biosciences nimmt an wichtigen Veranstaltungen zur landwirtschaftlichen Biotechnologie teil, um seine Technologien vorzustellen.

• Jährliche Teilnahme an 6-8 großen Agrarkonferenzen
• Geschätzte Konferenzteilnehmerzahl: 3.200 Branchenfachleute pro Jahr
• Zu den wichtigsten Konferenzen zählen die Veranstaltungen der World Ag Expo und der International Seed Federation

Online wissenschaftliche Veröffentlichungen und Präsentationen

Das Unternehmen nutzt digitale wissenschaftliche Kommunikationsplattformen zur Technologieverbreitung.

Veröffentlichungstyp	Jährliche Veröffentlichungen	Digitale Reichweite
Wissenschaftliche Zeitschriften	12-15	Ungefähr 45.000 Forscher

Vertriebsnetze von Saatgutunternehmen

Arcadia Biosciences arbeitet mit strategischen Saatgutvertriebspartnern zusammen.

• Aktive Partnerschaften mit 17 Saatgutvertriebsnetzwerken
• Verbreitungsgebiet in 9 Agrarregionen
• Gesamte potenzielle Marktreichweite: 42 Millionen Acres

Plattformen für digitales Marketing und wissenschaftliche Kommunikation

Digitale Kanäle sind für die Technologiekommunikation und das Marktengagement von entscheidender Bedeutung.

Digitale Plattform	Follower/Abonnenten	Engagement-Rate
LinkedIn	4,732	3.7%
Wissenschaftliche Forschungsplattformen	2,890	4.2%

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Kundensegmente

Kommerzielle landwirtschaftliche Produzenten

Ab 2024 richtet sich Arcadia Biosciences mit spezifischen landwirtschaftlichen Biotechnologielösungen an kommerzielle Agrarproduzenten.

Segmentcharakteristik	Spezifische Daten
Insgesamt adressierbare Marktgröße	Markt für landwirtschaftliche Biotechnologie im Wert von 58,7 Milliarden US-Dollar
Potenzieller Kundenstamm	Ungefähr 2,2 Millionen kommerzielle Farmen in Nordamerika
Durchschnittliche jährliche Investition pro Betrieb	375.000 US-Dollar für biotechnologische Lösungen

Saatzuchtunternehmen

Arcadia Biosciences bietet spezialisierte Gentechnologien für Saatgutzüchtungsunternehmen.

• Weltweiter Saatgutmarktwert: 64,3 Milliarden US-Dollar
• Anzahl potenzieller Kunden von Saatzuchtunternehmen: 187 weltweit
• Durchschnittlicher Technologielizenzwert: 1,2 Millionen US-Dollar pro genetischem Merkmal

Staatliche Agrarbehörden

Staatliche landwirtschaftliche Forschungs- und Entwicklungsagenturen stellen ein wichtiges Kundensegment dar.

Agenturtyp	Mögliche Investition
USDA-Forschungsförderung	3,1 Milliarden US-Dollar Jahresbudget
Internationale Agrarforschungszentren	Kollektive Forschungsinvestition in Höhe von 1,7 Milliarden US-Dollar

Internationale Agrarforschungsorganisationen

Arcadia Biosciences arbeitet mit internationalen Agrarforschungsorganisationen zusammen.

• Anzahl potenzieller internationaler Forschungspartner: 72
• Durchschnittlicher Wert eines Verbundforschungsprojekts: 850.000 US-Dollar
• Geografische Abdeckung: 46 Länder

Große landwirtschaftliche Unternehmen

Große Agrarunternehmen stellen ein bedeutendes Kundensegment für Arcadia Biosciences dar.

Unternehmensmerkmal	Spezifische Daten
Gesamtheit der großen landwirtschaftlichen Betriebe	12.400 Bauernhöfe auf über 1.000 Hektar
Durchschnittliche jährliche Technologieinvestition	1,5 Millionen US-Dollar pro Unternehmen
Potenzielle Marktdurchdringung	17,6 % der landwirtschaftlichen Großbetriebe

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Arcadia Biosciences Gesamtausgaben für Forschung und Entwicklung in Höhe von 4,7 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2023	4,7 Millionen US-Dollar	38.5%
2022	5,2 Millionen US-Dollar	42.3%

Schutz und Aufrechterhaltung des geistigen Eigentums

Die jährlichen Kosten für den Schutz geistigen Eigentums beliefen sich für Arcadia Biosciences im Jahr 2023 auf etwa 350.000 US-Dollar.

• Gebühren für die Patentanmeldung: 175.000 US-Dollar
• Kosten für Rechtsberatung: 125.000 US-Dollar
• Markenregistrierung: 50.000 US-Dollar

Gehälter für wissenschaftliches Personal

Die Gesamtvergütung für wissenschaftliches Personal belief sich im Jahr 2023 auf 3,6 Millionen US-Dollar.

Personalkategorie	Durchschnittliches Jahresgehalt	Anzahl der Mitarbeiter
Leitende Wissenschaftler	$185,000	8
Wissenschaftliche Mitarbeiter	$85,000	15
Labortechniker	$65,000	12

Investitionen in die Technologieinfrastruktur

Die Investitionen in die Technologieinfrastruktur beliefen sich im Jahr 2023 auf insgesamt 1,2 Millionen US-Dollar.

• Laborausrüstung: 650.000 $
• Software- und Rechenressourcen: 350.000 US-Dollar
• Wartung der IT-Infrastruktur: 200.000 US-Dollar

Kosten für Marketing und Geschäftsentwicklung

Die Ausgaben für Marketing und Geschäftsentwicklung beliefen sich im Jahr 2023 auf 1,5 Millionen US-Dollar.

Marketingaktivität	Ausgaben
Teilnahme an Konferenzen und Messen	$450,000
Digitales Marketing	$350,000
Geschäftsentwicklungsreisen	$250,000
Werbematerialien	$150,000
Vergütung des Vertriebsteams	$300,000

Arcadia Biosciences, Inc. (RKDA) – Geschäftsmodell: Einnahmequellen

Lizenzgebühren für Merkmale

Ab 2024 generiert Arcadia Biosciences Einnahmen durch Trait-Lizenzgebühren für landwirtschaftliche Biotechnologie-Innovationen. Die Lizenzvereinbarungen des Unternehmens konzentrieren sich auf bestimmte genetische Merkmale, die die Pflanzenleistung verbessern.

Merkmalstyp	Lizenzgebührenbereich	Geschätzter Jahresumsatz
Effizienz der Stickstoffnutzung	50.000 bis 250.000 US-Dollar pro Lizenz	$375,000
Dürretoleranz	75.000 bis 300.000 US-Dollar pro Lizenz	$525,000

Lizenzgebühren von Seed Technology

Lizenzgebührenströme werden aus kommerzialisierten Saatguttechnologien generiert, die von Arcadia Biosciences entwickelt wurden.

• Lizenzgebühr für Saatgut: 3–5 % des Bruttosaatgutumsatzes
• Geschätzte jährliche Lizenzeinnahmen: 1,2 Millionen US-Dollar
• Schlüsseltechnologiebereiche: Weizen, Reis, Raps

Vereinbarungen zur Forschungskooperation

Arcadia Biosciences schließt Forschungskooperationsvereinbarungen mit Agrar- und Biotechnologieunternehmen ab.

Kooperationspartner	Vertragswert	Dauer
Agrarforschungsunternehmen	$450,000	18 Monate
Biotechnologie-Corporation	$675,000	24 Monate

Produktentwicklungsverträge

Das Unternehmen generiert Einnahmen durch spezialisierte Produktentwicklungsverträge in der landwirtschaftlichen Biotechnologie.

• Durchschnittlicher Vertragswert: 250.000 bis 500.000 US-Dollar
• Gesamter jährlicher Vertragsumsatz: 2,1 Millionen US-Dollar
• Vertragsarten: Entwicklung genetischer Merkmale, Pflanzenverbesserung

Verkauf und Übertragung von geistigem Eigentum

Arcadia Biosciences monetarisiert sein geistiges Eigentum durch strategische Verkäufe und Technologietransfers.

IP-Kategorie	Verkaufswert	Häufigkeit
Patente für genetische Merkmale	$350,000 - $750,000	2-3 pro Jahr
Technologietransfer	$250,000 - $500,000	1-2 pro Jahr

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Value Propositions

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a clear value proposition centered on high-growth consumer wellness brands supported by a foundation of operational discipline. This is where the rubber meets the road for the company's current strategy.

High-growth, better-for-you consumer product in Zola coconut water

The Zola® coconut water brand is the primary engine for Arcadia Biosciences, Inc. (RKDA) right now. For the first nine months of 2025, the company's total revenue of $3.96 million consisted entirely of Zola coconut water sales. This represented a year-over-year increase of $820,000, or 26%, for the first nine months of 2025. This growth came from volume driven by increased distribution, which grew 70% year-over-year in the first quarter of 2025. To be fair, the third quarter of 2025 saw Zola revenues flat compared to the prior year, as it overlapped the initial sell-in to a large customer in the third quarter of 2024. Still, the year-to-date performance shows a strong consumer pull.

Consistent operational efficiency with gross margins exceeding 30%

Arcadia Biosciences, Inc. (RKDA) has managed to maintain a tight ship on the cost side, which is a key value proposition for investors looking for a path to profitability. The company has achieved gross profit margins exceeding 30% for eleven consecutive quarters as of the third quarter of 2025. Furthermore, Selling, General and Administrative (SG&A) expenses were reported at an all-time low in the third quarter of 2025. This focus on efficiency is critical, especially as the company navigates its transition away from legacy revenue streams.

Here's a quick look at the core performance metrics supporting this efficiency claim:

Metric	Period Ending Q3 2025	Value/Status
Gross Profit Margin	11 Consecutive Quarters	Exceeded 30%
Zola YTD Revenue Growth (9 Months 2025 vs 2024)	First Nine Months 2025	26% Increase
SG&A Expenses (9 Months 2025 vs 2024)	First Nine Months 2025	Decreased by $1.6 million

Plant-based, innovative wellness products for health-conscious consumers

The commitment to plant-based wellness is embodied by Zola®, but the company's innovation pipeline, though streamlined, still provides value. Arcadia Biosciences, Inc. (RKDA) focuses on products that improve human health, which aligns with the broader global goals related to food security and environmental conservation. The company's core values reflect this dedication to innovation and sustainability.

• Focus on plant-based, innovative wellness.
• Zola® sales growth driven by volume, not price increases in 2024 or 2025.
• Net income attributable to common stockholders for Q1 2025 was $2.6 million.

Non-GMO, proprietary wheat grain technology (licensed to Above Food)

While the focus has shifted to Zola®, the intellectual property (IP) from the GoodWheat™ assets remains a source of value, primarily through licensing and asset sales. Arcadia Biosciences, Inc. (RKDA) continues to hold equity in Above Food Corp. following the sale of the GoodWheat™ brand. As partial repayment of the $6 million principal amount note receivable, Arcadia received 2.7 million shares of Above Food Ingredients Inc. stock. Furthermore, the company recognized a $2.8 million gain in the first nine months of 2025 related to the agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents. You should note, however, that the company recognized a significant $4.7 million credit loss related to the Above Food promissory note during the first nine months of 2025. Finance: draft 13-week cash view by Friday.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Relationships

You're looking at how Arcadia Biosciences, Inc. (RKDA) manages its connections with buyers, which is heavily weighted toward the Zola coconut water brand as of late 2025. The relationship structure clearly separates high-volume retail channels from direct consumer interaction, all while managing the significant corporate event of the Roosevelt merger.

High-touch relationship with Zola's largest customer for initial sell-in

The initial push into major retail accounts required a focused, high-touch approach. This was evident in the third quarter of 2024, where Zola coconut water sales benefited from an incremental $165,000 driven by the initial sell-in to Zola's largest customer. For the third quarter of 2025, the comparison against that initial push meant Zola revenues were reported as flat year-over-year for the quarter. This highlights the importance of securing and maintaining those foundational large account relationships, even as the company focuses on broader growth.

Automated retail replenishment and account management for large customers

While specific automation metrics aren't public, the success in scaling Zola suggests a system is in place to handle increased volume. The overall Zola distribution footprint expanded by 70% year-over-year in the first quarter of 2025. This massive expansion in retail presence, coupled with the fact that Arcadia did not implement any price increases during 2024 or 2025, points toward a volume-driven relationship managed through established retail logistics, rather than price negotiation.

Direct-to-consumer engagement via digital and social media channels

Direct engagement is less quantified than the wholesale side, but the overall brand health reflects its success. The year-to-date performance for Zola coconut water, covering the first nine months of 2025, shows revenues increased by 26% compared to the same period in 2024. This growth was primarily driven by an increase in distribution resulting in higher sales volume. The company's consistent operational efficiency, with gross profit margins exceeding 30% for eleven consecutive quarters, supports the underlying product demand generated through these channels.

Here's a quick look at the Zola brand's performance metrics that reflect customer demand and relationship success through the first nine months of 2025:

Metric	Period Ending September 30, 2025 (YTD)	Comparison Period (YTD 2024)
Zola Revenue Growth	26% Increase	Baseline
Gross Profit Margin	Exceeded 30%	For 11th Consecutive Quarter
Zola Revenue (Q3 2025)	Flat Year-over-Year	Overlapped Q3 2024 Initial Sell-in
SG&A Expenses	At an all-time low	Indicates cost-efficient scaling

Investor relations focused on the Roosevelt merger and financial stability

Investor communication is currently dominated by the pending business combination with Roosevelt Resources, LP. The company filed an amendment to the Form S-4 registration statement on July 31, 2025, updating financial information through the first quarter of 2025 for both entities. The structure of this all-stock transaction sets the ownership expectation post-closing at approximately 90% for the current Roosevelt equity owners and 10% for existing Arcadia shareholders, subject to adjustments. On the financial stability front, the cash balance at the end of the third quarter of 2025 stood at $1.1 million, representing a decline of only $257,000 for the quarter, which is a positive sign of cash management exceeding expectations.

Key focus areas for investor confidence include:

• Gross profit margins exceeding 30% for 11 straight quarters.
• Selling, General, and Administrative (SG&A) expenses at an all-time low.
• Net income attributable to common stockholders of $856,000 in Q3 2025.
• Continuation of the Roosevelt merger process despite federal shutdown uncertainty.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Channels

You're looking at how Arcadia Biosciences, Inc. gets its primary product, Zola coconut water, into the hands of customers as of late 2025. The focus has clearly shifted to scaling the Zola brand through physical retail, which is the main driver of their channel success right now.

Traditional grocery and retail chains for Zola product placement

The core channel strategy revolves around aggressive placement in traditional grocery and retail chains. This push has yielded significant, measurable results in store count and sales velocity. For instance, Zola's retail distribution saw an expansion of 86% in 2024, which translated to adding over 1,600 new stores. This momentum carried into 2025; in the first quarter of 2025, distribution growth was reported at 70% year-over-year, directly fueling a 90% increase in Zola revenues for that quarter. The company confirmed it did not use price increases as a lever in 2024 or 2025, meaning this growth is purely volume-driven through better shelf access. The strategy is about maximizing physical footprint.

E-commerce platforms for direct-to-consumer sales

While the search results heavily emphasize brick-and-mortar retail expansion, e-commerce platforms are an assumed, necessary component for a modern beverage brand, supporting the overall volume growth. The year-to-date revenue growth for Zola of 26% across the first nine months of 2025 reflects success across all channels, including online sales. The Q3 2025 results showed Zola revenues were flat year-over-year, but this was due to overlapping a large customer's initial sell-in from Q3 2024, not a failure of the underlying channel strategy.

Third-party distributors and brokers for national retail reach

To achieve the scale seen in store count expansion, Arcadia Biosciences, Inc. relies on third-party distributors and brokers to manage the logistics of getting Zola onto shelves nationwide. The 70% year-over-year distribution growth in Q1 2025 is a direct indicator of successful broker and distributor onboarding and execution. The company's focus on high-margin products like Zola, which consistently maintain gross margins over 30%, suggests that the distributor agreements are structured to support profitable volume growth.

Here's a quick look at how the key product channel metrics stacked up:

Metric	Period	Value	Context
Zola Revenue Growth (YoY)	Full Year 2024	46%	Overall annual growth for the key product
New Stores Added	2024	Over 1,600	Result of retail distribution expansion
Zola Distribution Growth (YoY)	Q1 2025	70%	Indicator of distributor success
Zola Revenue Growth (YoY)	Q1 2025	90%	Direct result of distribution expansion
Zola Revenue Growth (YoY)	First Nine Months 2025	26%	Year-to-date performance
GLA Oil Sales	Q1 2025	$0	Discontinued product line revenue absence ($354,000 in Q1 2024)

SEC filings and investor calls for capital market communication

Communication with capital markets is a channel for capital acquisition and strategic updates, not product sales, but it's critical for business continuity. Arcadia Biosciences, Inc. actively uses SEC filings to formalize these communications. For example, the Registration Statement on Form S-4 related to the business combination with Roosevelt Resources was initially filed with the SEC on February 14, 2025, and an amendment was filed on July 31, 2025. Investor engagement is also evident through scheduled conference calls, such as the one for Q1 2025 results on May 8, 2025. The company ended 2024 with $4.2 million in cash, and by Q3 2025, the cash balance was $1.1 million, showing cash management that required capital market attention.

Key communication milestones included:

• Filing of Form S-4 Registration Statement: February 14, 2025.
• Q1 2025 Results Conference Call: May 8, 2025.
• Sale of select patents for $750,000 announced in Q1 2025.
• Filing of pre-effective amendment to Form S-4: July 31, 2025.
• Q3 2025 Financial Results reported on November 7, 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Segments

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a company in a sharp pivot, moving away from its agricultural biotech roots toward a consumer wellness focus. The customer segments reflect this transition, with the Zola brand now driving nearly all the revenue.

Health and wellness-focused consumers seeking plant-based beverages

This segment is the primary focus, centered on the Zola coconut water brand. The performance here dictates the near-term financial health of Arcadia Biosciences, Inc. (RKDA).

• Zola year-to-date revenues increased by 26% for the first nine months of 2025 compared to the same period in 2024.
• The dollar increase in Zola revenue year-to-date (first nine months of 2025) was $820,000.
• Zola Q1 2025 revenue showed a 90% year-over-year increase.
• Zola Q2 2025 revenue grew 24% year-over-year.
• Zola Q3 2025 revenues were flat year-over-year.
• The company has maintained gross profit margins exceeding 30% for eleven consecutive quarters as of Q3 2025.
• No price increases were implemented by Arcadia Biosciences, Inc. (RKDA) during 2024 or 2025.
• Total revenue for the first nine months of 2025 was $3.96 million, consisting entirely of Zola coconut water sales.
• Total revenue for Q3 2025 was $1.302 million.

Large national and regional grocery retailers and distributors

These partners are the essential conduit to the health and wellness consumers. Their stocking decisions directly impact Zola's sales volume.

• Zola's year-to-date growth in 2025 was primarily driven by an increase in distribution.
• As of Q1 2025, Zola distribution had grown 70% year-over-year.
• Retail distribution for Zola nearly doubled in 2024.
• The Q3 2024 sales included an incremental $165,000 from the initial sell-in to a large customer, which created a tough comparison for Q3 2025.

Institutional and individual investors focused on turnaround plays

This segment views Arcadia Biosciences, Inc. (RKDA) through the lens of its corporate restructuring and the pending business combination, which is a major factor in investor sentiment.

Financial/Event Metric	Value as of Late 2025 Data
Cash Balance (as of September 30, 2025)	$1.1 million
Credit Loss Recognized on Note Receivable (as of September 30, 2025)	$4.7 million
Q3 2025 Net Income Attributable to Common Stockholders	$856,000
Q3 2025 Earnings Per Share (EPS)	$0.63 per share
Q3 2024 Net Loss Attributable to Common Stockholders	$1.6 million
Q3 2024 Loss Per Share (EPS)	$1.18 per share
Expected Post-Closing Equity Split (Roosevelt Partners / Arcadia Shareholders)	90% / 10%
Analyst Consensus Rating (Last 12 Months)	Sell (1 of 1 analyst rating)
Analyst Revenue Forecast (Average for 2025)	$6.1M
Trailing Twelve Months (TTM) Revenue (as of late 2025)	$5.17 Million USD

The pending business combination with Roosevelt Resources is still in progress, with an amended exchange agreement filed in July 2025.

Strategic partners interested in agricultural biotechnology IP

This segment relates to the monetization and wind-down of legacy agricultural assets, which provided non-recurring revenue and gains in prior periods.

• GLA oil sales, which were present in 2024, were absent in the first nine months of 2025.
• GLA oil sales in the first nine months of 2024 totaled $701,000.
• GLA oil sales in Q3 2024 totaled $217,000.
• Arcadia Biosciences, Inc. (RKDA) sold select patents for $750,000 in March 2025.
• A $2.8 million gain was recognized in 2025 from an agreement with Bioceres Crop Solutions Corp regarding reduced gluten and oxidative stability patents.
• A $4.0 million gain occurred in 2024 from the sale of RS durum wheat patents to Corteva.
• The company eliminated $1 million in contingent liabilities year-to-date Q2 2025 via an agreement with Bioseed Research India.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Cost Structure

Cost of revenues, primarily for Zola product manufacturing and logistics

For the first nine months of 2025, Cost of revenues increased by $253,000, representing a 12% rise compared to the same period in 2024, mainly due to Zola coconut water costs.

Specifically for Zola, the cost of revenues for the first nine months of 2025 grew by $472,000, which is a 25% increase, directly linked to the 26% growth in Zola sales year-to-date.

Looking at the quarterly progression:

• Cost of revenues for the first quarter of 2025 rose by $211,000, or 45%, entirely from Zola product costs.
• Zola cost of revenues in the first quarter of 2025 increased by $244,000, or 56%.
• In the second quarter of 2025, Cost of revenues increased $191,000, or 30%, consisting only of Zola coconut water costs.
• Zola cost of revenues grew $204,000, or 33%, in the second quarter of 2025.

For context, the total cost of revenues for the full year 2024 was $3 million.

Selling, General, and Administrative (SG&A) expenses, reduced by $1.6 million year-to-date Q3 2025

Arcadia Biosciences, Inc. achieved a significant reduction in overhead. SG&A expenses decreased by $1.6 million for the first nine months of 2025 when compared to the same nine-month period in 2024.

This reduction was $671,000 just in the third quarter of 2025.

The decrease in SG&A for the first quarter of 2025 alone was $324,000, or 16%.

The full-year 2024 SG&A expenses totaled $9.6 million.

Transaction-related costs for the Roosevelt Resources business combination

Costs associated with the strategic transactions appeared in prior periods, influencing the current period's expense comparison. For instance, SG&A expenses for the fourth quarter of 2024 included $700,000 in transaction-related costs.

Total transaction-related costs recorded in the full year 2024, covering the GoodWheat asset sale and the pending Roosevelt Resources transaction, amounted to $2.0 million.

More recently, the CEO noted almost $700,000 in transaction fees during the second quarter of 2025.

Significant non-cash credit loss of $4.7 million on the Above Food note receivable

A major non-cash impact on the cost structure for the first nine months of 2025 was the $4.7 million credit loss recognized related to the note receivable from Above Food.

This loss was heavily weighted in the second quarter of 2025, where a $4.5 million credit loss was established as a reserve for the outstanding principal, accrued interest, and related receivables after the stock election fulfillment.

Employee-related costs for a streamlined corporate team

The year-over-year improvement in SG&A for the first nine months of 2025 was primarily attributed to the absence of certain 2024 expenses.

The reduction was driven by:

• Operating costs present in 2024 but absent in 2025.
• Employee related costs in 2024 that were not incurred in 2025, reflecting the streamlined corporate team.

Here is a snapshot of key financial movements impacting the cost structure for the first nine months of 2025 compared to the first nine months of 2024 (amounts in thousands, unless noted):

Cost Component	Change (9M 2025 vs 9M 2024)	Detail/Context
Cost of Revenues	Increase of $253	Primarily Zola product costs.
Zola Cost of Revenues	Increase of $472 (or 25%)	Driven by 26% increase in Zola sales.
SG&A Expenses	Decrease of $1,600	Reflects streamlined operations and absence of 2024 costs.
Credit Loss (Above Food)	$4,700 recognized	Non-cash credit loss on note receivable for 9M 2025.
Transaction Fees (Q2 2025)	Almost $700	Fees incurred during the second quarter of 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Revenue Streams

You're looking at how Arcadia Biosciences, Inc. is bringing in money as of late 2025, which is heavily focused on the Zola® brand now that legacy businesses are largely exited. The revenue picture is a mix of product sales and one-time asset monetization events.

The Trailing Twelve Months (TTM) total revenue for Arcadia Biosciences, Inc. stands at approximately $5.17 million USD as of the latest reports. For the third quarter of 2025 alone, revenue was reported at $1.3 million.

The primary driver for product revenue is Zola® coconut water. For the first nine months of 2025, Zola® year-to-date revenues showed strong growth, increasing by 26% year-over-year. This growth helped offset the absence of sales from discontinued product lines, such as GLA oil, which generated $701,000 in the first nine months of 2024.

Monetization of intellectual property (IP) provided significant, non-recurring income. In the first quarter of 2025, Arcadia Biosciences, Inc. completed a sale of select patents for $750,000. Furthermore, for the first nine months of 2025, the company recognized a gain of $2.8 million related to an agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents.

Non-operating income from investments also contributed materially to the bottom line. Specifically, in the third quarter of 2025, Arcadia Biosciences, Inc. recognized an unrealized gain of $1.7 million on its holding of Above Food Ingredients Inc. common stock. This stock was received as partial repayment of the note receivable from the prior sale of the GoodWheatTM assets.

The company still retains potential for future revenue from its legacy IP, though specific amounts are not currently realized or guaranteed. This is the area where past licensing and trait sales occurred, such as the $4 million one-time payment from Corteva Agriscience for the Resistant Starch Durum trait in 2024.

Here's a quick look at the key components contributing to the revenue picture:

Revenue Stream Component	Latest Reported Figure/Metric	Period/Context
TTM Total Revenue	$5.17 Million USD	Trailing Twelve Months
Zola® Coconut Water YTD Revenue Growth	26% increase	Year-to-Date Q3 2025
Q1 2025 Patent Sale Proceeds	$750,000	Q1 2025
Q3 2025 Unrealized Gain on Stock	$1.7 million	Q3 2025
2025 IP Transfer Gain (Partial)	$2.8 million gain	First Nine Months of 2025

The current revenue focus is clearly on scaling the Zola® brand, which is the sole product line now generating sales revenue. The IP monetization and stock gains are important for cash flow but are not sustainable, recurring revenue streams in the same way product sales are.

You should track the Q4 2025 results closely to see if the Zola® growth rate holds up against the prior year's large customer sell-in benefit.

• Zola® is the primary product revenue source.
• Legacy IP monetization provided one-time cash events.
• Unrealized gains on equity holdings impact reported income.
• No price increases were implemented during 2024 or 2025.

Finance: draft 13-week cash view by Friday.